{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T19:49:12Z","timestamp":1770839352700,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T00:00:00Z","timestamp":1677196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T00:00:00Z","timestamp":1677196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s00520-023-07634-5","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T06:03:12Z","timestamp":1677218592000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Hair loss during and after breast cancer therapy"],"prefix":"10.1007","volume":"31","author":[{"given":"Lucy","family":"Rose","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Lustberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn J.","family":"Ruddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Cathcart-Rake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Loprinzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brittany","family":"Dulmage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,24]]},"reference":[{"issue":"5","key":"7634_CR1","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.jaad.2018.03.055","volume":"80","author":"A Martinez","year":"2019","unstructured":"Martinez A, Shapiro J, Goldfarb S, Nangia J, Jiminez J, Paus R, Lacoutoure M (2019) CME Part 1: Hair disorders in cancer patients. J Am Acad Dermatol 80(5):1179\u20131196. https:\/\/doi.org\/10.1016\/j.jaad.2018.03.055","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"7634_CR2","first-page":"5","volume":"15","author":"R Treub","year":"2010","unstructured":"Treub R (2010) Chemotherapy induced hair loss. Skin Ther Lett 15(7):5\u20137","journal-title":"Skin Ther Lett"},{"issue":"10","key":"7634_CR3","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1634\/theoncologist.2013-0193","volume":"18","author":"V Saggar","year":"2013","unstructured":"Saggar V et al (2013) Alopecia with endocrine therapies in patients with cancer. Oncologist 18(10):1126\u20131134","journal-title":"Oncologist"},{"key":"7634_CR4","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00520-007-0318-8","volume":"3","author":"M Hackbarth","year":"2008","unstructured":"Hackbarth M, Haas N, Fotopoulou C, Lichtenegger W, Sehouli J (2008) Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women\u2019s cancers. Results of a prospective study. Support Care Cancer 3:267\u2013273","journal-title":"Support Care Cancer"},{"issue":"5","key":"7634_CR5","doi-asserted-by":"publisher","first-page":"469","DOI":"10.5301\/tj.5000376","volume":"101","author":"Moscetti","year":"2015","unstructured":"Moscetti et al (2015) Adjuvant aromatase inhibitor therapy in early breast cancer: what factors lead patients to discontinue treatment? Tumori 101(5):469\u2013473","journal-title":"Tumori"},{"key":"7634_CR6","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1242\/jcs.02793","volume":"119","author":"L Alonso","year":"2006","unstructured":"Alonso L, Fuchs E (2006) The hair cycle. J Cell Sci 119:391\u2013393","journal-title":"J Cell Sci"},{"issue":"6","key":"7634_CR7","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1007\/s00520-019-05169-2","volume":"28","author":"JR Stoehr","year":"2020","unstructured":"Stoehr JR, Kosche C, Choi JN (2020) Permanent chemotherapy-induced alopecia: awareness and attitudes among health care providers. Support Care Cancer 28(6):2887\u20132890","journal-title":"Support Care Cancer"},{"issue":"3","key":"7634_CR8","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1634\/theoncologist.2018-0184","volume":"24","author":"D Kang","year":"2019","unstructured":"Kang D, Kim I, Choi E et al (2019) Permanent chemotherapy-induced alopecia in patients with breast cancer: a 3-year prospective cohort study. Oncologist 24(3):414\u2013420","journal-title":"Oncologist"},{"issue":"2","key":"7634_CR9","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1016\/S1470-2045(12)70553-3","volume":"14","author":"R Paus","year":"2013","unstructured":"Paus R, Haslam IS, Sharov AA, Botchkarev VA (2013) Pathobiology of chemotherapy-induced hair loss. Lancet Oncol 14(2):e50\u2013e59. https:\/\/doi.org\/10.1016\/S1470-2045(12)70553-3","journal-title":"Lancet Oncol"},{"issue":"3","key":"7634_CR10","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.jaad.2010.03.020","volume":"64","author":"I Palamaras","year":"2011","unstructured":"Palamaras I, Misciali C, Vincenzi C, Robles WS, Tosti A (2011) Permanent chemotherapy-induced alopecia: a review. J Am Acad Dermatol 64(3):604\u2013606. https:\/\/doi.org\/10.1016\/j.jaad.2010.03.020","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"7634_CR11","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1046\/j.1440-0960.2000.00405.x","volume":"41","author":"D Tran","year":"2000","unstructured":"Tran D, Sinclair RD, Schwarer AP, Chow CW (2000) Permanent alopecia following chemotherapy and bone marrow transplantation. Australas J Dermatol 41(2):106\u2013108. https:\/\/doi.org\/10.1046\/j.1440-0960.2000.00405.x","journal-title":"Australas J Dermatol"},{"issue":"6","key":"7634_CR12","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1590\/abd1806-4841.20154013","volume":"90","author":"FM Basilio","year":"2015","unstructured":"Basilio FM, Brenner FM, Werner B, Rastelli GJ (2015) Clinical and histological study of permanent alopecia after bone marrow transplantation. An Bras Dermatol 90(6):814\u2013821. https:\/\/doi.org\/10.1590\/abd1806-4841.20154013","journal-title":"An Bras Dermatol"},{"key":"7634_CR13","doi-asserted-by":"crossref","unstructured":"E Cathcart-Rake, CL Loprinzi, F Couch, J Olson, B Dulmage, M Lustberg, N Larson, KJ Ruddy (2022) Eyebrow\/eyelash loss among survivors [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7\u201310; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res, 82(4 Suppl):Abstract nr P4\u201310\u201311","DOI":"10.1158\/1538-7445.SABCS21-P4-10-11"},{"key":"7634_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0208118","author":"T Wantanabe","year":"2019","unstructured":"Wantanabe T et al (2019) A multicenter survey of temporal changes in chemotherapy-induced hair loss in breast cancer patients. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0208118","journal-title":"PLoS ONE"},{"key":"7634_CR15","unstructured":"The Science of Scalp Cooling. Paxman Scalp Cooling. https:\/\/paxmanscalpcooling.com\/research\/the-science\/. Accessed 15 Aug 2022"},{"key":"7634_CR16","unstructured":"Cold Caps and Scalp Cooling Systems. https:\/\/www.breastcancer.org\/treatment-side-effects\/hair-loss\/cold-caps-scalp-cooling. Accessed 15 Aug 2022"},{"issue":"3","key":"7634_CR17","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1093\/annonc\/mdi088","volume":"16","author":"E Grevelman","year":"2005","unstructured":"Grevelman E, Breed W (2005) Prevention of chemotherapy-induced hair loss by scalp cooling. Ann Oncol 16(3):352\u2013358. https:\/\/doi.org\/10.1093\/annonc\/mdi088","journal-title":"Ann Oncol"},{"issue":"4","key":"7634_CR18","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3109\/0284186X.2012.658966","volume":"51","author":"J Van den Hurk","year":"2012","unstructured":"Van den Hurk J, Peerbooms M, van de Poll-Franse L, Nortier J, Coebergh J, Breed W (2012) Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients - results of the Dutch Scalp Cooling Registry. Acta Oncol 51(4):497\u2013504. https:\/\/doi.org\/10.3109\/0284186X.2012.658966","journal-title":"Acta Oncol"},{"key":"7634_CR19","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.clbc.2015.01.003","volume":"5","author":"T Cigler","year":"2015","unstructured":"Cigler T, Isseroff D, Fiederlein B, Schneider S, Chuang E, Vahdat L, Moore A (2015) Efficacy of scalp cooling in preventing chemotherapy-induced alopecia in breast cancer patients receiving adjuvant docetaxel and cyclophosphamide chemotherapy. Clin Breast Cancer 5:332\u2013334. https:\/\/doi.org\/10.1016\/j.clbc.2015.01.003","journal-title":"Clin Breast Cancer"},{"key":"7634_CR20","unstructured":"A Degree of Control: A Guide to Scalp Cooling. Paxman US Incorporated. https:\/\/www.stlukes-stl.com\/services\/womens-services\/documents\/paxman-scalp-cooling-system.pdf. Accessed 15 Aug 2022"},{"issue":"4","key":"7634_CR21","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/onco.13690","volume":"26","author":"A Dilawari","year":"2021","unstructured":"Dilawari A, Gallagher C, Alintah P, Chitalia A, Tiwari S, Paxman R, Adams-Campbell L, Dash C (2021) Does scalp cooling have the same efficacy in black patients receiving chemotherapy for breast cancer? Oncologist 26(4):292-e548. https:\/\/doi.org\/10.1002\/onco.13690","journal-title":"Oncologist"},{"issue":"30","key":"7634_CR22","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.1200\/JCO.20.02130","volume":"38","author":"E Araoye","year":"2020","unstructured":"Araoye E, Stearns V, Aguh C (2020) Considerations for the use of scalp cooling devices in black patients. J Clin Oncol 38(30):3575\u20133576. https:\/\/doi.org\/10.1200\/JCO.20.02130","journal-title":"J Clin Oncol"},{"issue":"6","key":"7634_CR23","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1096\/fj.07-099424","volume":"22","author":"K Shorter","year":"2008","unstructured":"Shorter K, Farjo NP, Picksley SM, Randall VA (2008) Human hair follicles contain two forms of ATP-sensitive potassium channels, only one of which is sensitive to minoxidil. Faseb J 22(6):1725\u20131736. https:\/\/doi.org\/10.1096\/fj.07-099424","journal-title":"Faseb J"},{"key":"7634_CR24","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.2147\/DDDT.S214907","volume":"13","author":"P Suchonwanit","year":"2019","unstructured":"Suchonwanit P, Thammarucha S, Leerunyaku K (2019) Minoxidil and its use in hair disorders: a review. Drug Des Dev Theory 13:2777\u20132786. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6691938\/","journal-title":"Drug Des Dev Theory"},{"issue":"1","key":"7634_CR25","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0190-9622(96)90500-9","volume":"35","author":"M Duvic","year":"1996","unstructured":"Duvic M, Lemak NA, Valero V et al (1996) A randomized trial of minoxidil in chemotherapy-induced alopecia. J Am Acad Dermatol 35(1):74\u201378","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"7634_CR26","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/j.1365-2133.2009.09043.x","volume":"160","author":"C Prevezas","year":"2009","unstructured":"Prevezas C, Matard B, Pinquier L, Reygagne P (2009) Irreversible and severe alopecia following docetaxel or paclitaxel cytotoxic therapy for breast cancer. Br J Dermatol 160(4):883\u2013885","journal-title":"Br J Dermatol"},{"key":"7634_CR27","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jdcr.2022.01.035","volume":"22","author":"A Lyakhovitsky","year":"2022","unstructured":"Lyakhovitsky A, Segal O, Maly A, Zlotogorski A, Barzilai A (2022) Permanent chemotherapy-induced alopecia after hematopoietic stem cell transplant treated with low-dose minoxidil. JAAD Case Rep 22:64\u201367. https:\/\/pubmed.ncbi.nlm.nih.gov\/35321258\/","journal-title":"JAAD Case Rep"},{"issue":"3","key":"7634_CR28","doi-asserted-by":"publisher","first-page":"e2020074","DOI":"10.5826\/dpc.1003a74","volume":"10","author":"A Rossi","year":"2020","unstructured":"Rossi A, Caro G, Fortuna MC, Pigliacelli F, D\u2019Arino A, Carlesimo M (2020) Prevention and Treatment of Chemotherapy-Induced Alopecia. Dermatol Pract Concept 10(3):e2020074. https:\/\/doi.org\/10.5826\/dpc.1003a74","journal-title":"Dermatol Pract Concept"},{"key":"7634_CR29","doi-asserted-by":"publisher","unstructured":"Malkud S (2015) Telogen effluvium: a review. J Clin Diagn Res 9(9):WE01-3. https:\/\/doi.org\/10.7860\/JCDR\/2015\/15219.6492","DOI":"10.7860\/JCDR\/2015\/15219.6492"},{"key":"7634_CR30","doi-asserted-by":"publisher","unstructured":"Rebora A (2019) Telogen effluvium: a comprehensive review. Clin Cosmet Investig Dermatol 12:583\u2013590. https:\/\/doi.org\/10.2147\/CCID.S200471","DOI":"10.2147\/CCID.S200471"},{"issue":"3","key":"7634_CR31","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jdermsci.2021.01.007","volume":"101","author":"GO Chien Yin","year":"2021","unstructured":"Chien Yin GO, Siong-See JL, Wang ECE (2021) Telogen effluvium \u2013 a review of the science and current obstacles. J Dermatol Sci 101(3):156\u2013163","journal-title":"J Dermatol Sci"},{"issue":"5","key":"7634_CR32","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.jaad.2018.03.056","volume":"80","author":"A Freites-Martinez","year":"2019","unstructured":"Freites-Martinez A, Shapiro J, van den Hurk C et al (2019) Hair disorders in cancer survivors. J Am Acad Dermatol 80(5):1199\u20131213","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"7634_CR33","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1001\/jamadermatol.2018.0454","volume":"154","author":"A Freites-Martinez","year":"2018","unstructured":"Freites-Martinez A et al (2018) Endocrine therapy-induced alopecia in patients with breast cancer. JAMA Dermatol 154(6):670\u2013675","journal-title":"JAMA Dermatol"},{"issue":"10","key":"7634_CR34","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1634\/theoncologist.2013-0193","volume":"18","author":"V Saggar","year":"2013","unstructured":"Saggar V, Shenhong Wu, Dickler MN, Lacouture ME (2013) Alopecia with endocrine therapies in patients with cancer. Oncologist 18(10):1126\u20131134","journal-title":"Oncologist"},{"key":"7634_CR35","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.mehy.2014.01.016","volume":"82","author":"S Bhargava","year":"2014","unstructured":"Bhargava S (2014) Increased DHT levels in androgenic alopecia have been selected for to protect men from prostate cancer. Med Hypotheses 82:428\u2013432. https:\/\/doi.org\/10.1016\/j.mehy.2014.01.016","journal-title":"Med Hypotheses"},{"issue":"5","key":"7634_CR36","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.jaad.2018.03.055","volume":"80","author":"A Freites-Martinez","year":"2019","unstructured":"Freites-Martinez A, Shapiro J, Goldfarb S et al (2019) Hair disorders in patients with cancer. J Am Acad Dermatol 80(5):1179\u20131196","journal-title":"J Am Acad Dermatol"},{"key":"7634_CR37","doi-asserted-by":"crossref","unstructured":"Gallicchio L, Calhoun C, Helzlsouer K (2017) Hair loss associated with aromatase inhibitor treatment among breast cancer patients. J Clin Oncol. https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2017.35.15_suppl.e21619","DOI":"10.1200\/JCO.2017.35.15_suppl.e21619"},{"key":"7634_CR38","first-page":"799","volume":"10","author":"F Al-Niaimi","year":"2011","unstructured":"Al-Niaimi F, Lyon C (2011) Tamoxifen-induced hirsutism. J Drugs Dermatol 10:799\u2013801","journal-title":"J Drugs Dermatol"},{"key":"7634_CR39","doi-asserted-by":"publisher","first-page":"469","DOI":"10.5301\/tj.5000376","volume":"101","author":"L Moscetti","year":"2015","unstructured":"Moscetti L, Agnese Fabbri M, Sperduti I, Fabrizio N et al (2015) Adjuvant aromatase inhibitor therapy in early breast cancer: what factors lead patients to discontinue treatment? Tumori 101:469\u2013473","journal-title":"Tumori"},{"key":"7634_CR40","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41523-019-0121-y","volume":"5","author":"A Marra","year":"2019","unstructured":"Marra A, Curigliano G (2019) Are all cyclin-dependent kinases 4\/6 inhibitors created equal? NPJ Breast Cancer 5:27. https:\/\/doi.org\/10.1038\/s41523-019-0121-y","journal-title":"NPJ Breast Cancer"},{"issue":"6","key":"7634_CR41","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1080\/0284186X.2020.1738547","volume":"59","author":"D Eiger","year":"2020","unstructured":"Eiger D, Wagner M, Pond\u00e9 NF, Nogueira MS, Buisseret L, de Azambuja E (2020) The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4\/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC). Acta Oncol 59(6):723\u2013725. https:\/\/doi.org\/10.1080\/0284186X.2020.1738547","journal-title":"Acta Oncol"},{"key":"7634_CR42","doi-asserted-by":"publisher","first-page":"15_suppl","DOI":"10.1200\/JCO.2019.37.15_suppl.e12537","volume":"37","author":"D Chan","year":"2019","unstructured":"Chan D, Martinez ADF, Goldfarb SB, Modi S, Gajria D, Lacouture ME (2019) CDK4\/6 plus aromatase inhibitor-induced alopecia in breast cancer patients. J Clin Oncol 37:15_suppl (e12537-e12537)","journal-title":"J Clin Oncol"},{"issue":"11","key":"7634_CR43","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1093\/annonc\/mds095","volume":"23","author":"N Kluger","year":"2012","unstructured":"Kluger N, Jacot W, Frouin E et al (2012) Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil\/epirubicin\/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients. Ann Oncol 23(11):2879\u20132884. https:\/\/doi.org\/10.1093\/annonc\/mds095 (http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22571858)","journal-title":"Ann Oncol"},{"issue":"11","key":"7634_CR44","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s10552-014-0455-6","volume":"25","author":"RG Duijnhoven","year":"2014","unstructured":"Duijnhoven RG, Straus SM, Souverein PC et al (2014) Long-term use of 5alpha-reductase inhibitors and the risk of male breast cancer. Cancer Causes Control 25(11):1577\u20131582. https:\/\/doi.org\/10.1007\/s10552-014-0455-6","journal-title":"Cancer Causes Control"},{"issue":"5","key":"7634_CR45","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.juro.2013.04.132","volume":"190","author":"ST Bird","year":"2013","unstructured":"Bird ST, Brophy JM, Hartzema AG, Delaney JA, Etminan M (2013) Male breast cancer and 5alpha-reductase inhibitors finasteride and dutasteride. J Urol 190(5):1811\u20131814. https:\/\/doi.org\/10.1016\/j.juro.2013.04.132 (http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23665270)","journal-title":"J Urol"},{"issue":"1","key":"7634_CR46","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/cam4.1273","volume":"7","author":"M Meijer","year":"2018","unstructured":"Meijer M, Thygesen LC, Green A et al (2018) Finasteride treatment and male breast cancer: a register-based cohort study in four nordic countries. Cancer Med 7(1):254\u2013260","journal-title":"Cancer Med"},{"issue":"5","key":"7634_CR47","doi-asserted-by":"publisher","first-page":"490","DOI":"10.37349\/etat.2021.00059","volume":"2","author":"A Rossi","year":"2021","unstructured":"Rossi A, Caro G, Magri F, Fortuna MC, Carlesimo M (2021) Clinical aspect, pathogenesis and therapy options of alopecia induced by hormonal therapy for breast cancer. Explor Target Antitumor Ther 2(5):490\u2013495. https:\/\/doi.org\/10.37349\/etat.2021.00059","journal-title":"Explor Target Antitumor Ther"},{"key":"7634_CR48","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/09546634.2017.1341610","volume":"29","author":"A Rossi","year":"2018","unstructured":"Rossi A, Campo D, Fortuna MC, Garelli V, Pranteda G, De Vita G et al (2018) A preliminary study on topical cetirizine in the therapeutic management of androgenetic alopecia. J Dermatolog Treat 29:149\u2013151. https:\/\/doi.org\/10.1080\/09546634.2017.1341610","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"7634_CR49","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/ijc.28961","volume":"136","author":"CM Soref","year":"2015","unstructured":"Soref CM, Fahl WE (2015) A new strategy to prevent chemotherapy and radiotherapy-induced alopecia using topically applied vasoconstrictor. Int J Cancer 136(1):195\u2013203. https:\/\/doi.org\/10.1002\/ijc.28961","journal-title":"Int J Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-07634-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-023-07634-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-07634-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T06:08:34Z","timestamp":1678687714000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-023-07634-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,24]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["7634"],"URL":"https:\/\/doi.org\/10.1007\/s00520-023-07634-5","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,24]]},"assertion":[{"value":"4 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Loprinzi reports personal fees from PledPharma, personal fees from Disarm Therapeutics, personal fees from Veloxis, personal fees from Metys Pharmaceuticals, personal fees from OnQuality, personal fees from NKMax, personal fees from Novartis, personal fees from HengRui, personal fees from Osmol Therapeutics, Inc., personal fees from Grunenthal, personal fees from Neuropathix, personal fees from Denali therapeutics, personal fees from Bexion Pharmaceuticals, and personal fees from Pfizer, outside the submitted work.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"186"}}